Fontan and the pulmonary circulation: A potential role for new pulmonary hypertension therapies

Heart

Volumn 96, Issue 12, 2010, Pages 911-916

  Beghetti, Maurice ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BUDESONIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MILRINONE; NITRIC OXIDE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SOMATOSTATIN; SPIRONOLACTONE;

CAVOPULMONARY CONNECTION; FONTAN PROCEDURE; HEART TRANSPLANTATION; HUMAN; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; MORBIDITY; PORTOPULMONARY HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; PULMONARY HYPERTENSION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; PROTEIN-LOSING ENTEROPATHIES; PULMONARY CIRCULATION; SURVIVORS;

EID: 77953698264     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.193912     Document Type: Review

References (68)

1. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971;26:240-8.
2. de Leval MR. The Fontan circulation: a challenge to William Harvey? Nat Clin Pract Cardiovasc Med 2005;2:202-8.
3. Gewillig M. The Fontan circulation. Heart 2005;91:839-6.
4. d'Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation 2007;116(11 Suppl):I157-64.
5. Hosein RB, Clarke AJ, McGuirk SP, et al. Factors influencing early and late outcome following the Fontan procedure in the current era. The 'Two Commandments'? Eur J Cardiothorac Surg 2007;31:344-52.
6. Fontan F, Kirklin JW, Fernandez G, et al. Outcome after a "perfect" Fontan operation. Circulation 1990;81:1520-36.
7. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009,34:888-94.
8. Bassili A, Mokhtar SA, Dabous NI, et al. Congenital heart disease among school children in Alexandria, Egypt: an overview on prevalence and relative frequencies. J Trop Pediatr 2000;46:357-62.
9. Iyengar AJ, Shann F, Cochrane AD, et al. The Fontan procedure in Australia: a population-based study. J Thorac Cardiovasc Surg 2007;134:1353-64.
10. The Information Centre for health and social care Central Cardiac Audit Database. Specific Procedures National Data (2006-2007). http://www.ccad.org.uk/ 002/congenital.nsf/WBenchmarksYears?openview&RestrictToCategory= 2006&start=1&count=500 (accessed 15 Mar 2010).
11. Bridges ND, Mayer JE Jr, Lock JE, et al. Effect of baffle fenestration on outcome of the modified Fontan operation. Circulation 1992;86:1762-9.
12. Mitchell ME, Ittenbach RF, Gaynor JW, et al. Intermediate outcomes after the Fontan procedure in the current era. Thorac Cardiovasc Surg 2006;131:17-80.
13. Giardini A, Hager A, Napoleone CP, et al. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann Thorac Surg 2008;85:818-21.
14. Paridon SM, Mitchell PD, Colan SD, et al. A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J Am Coll Cardiol 2008;52:99-107.
15. Anderson PA, Sleeper LA, Mahony L, et al. Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol 2008;52:85-98. (Pubitemid 351885451)
16. Mertens L, Hagler DJ, Sauer U, et al. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998;115:1063-73.
17. Connor FL, Angelides S, Gibson M, et al. Successful resection of localized intestinal lymphangiectasia post-Fontan: role of (99m)technetium- dextran scintigraphy. Pediatrics 2003;112:e242-7.
18. Anne P, Du W, Mattoo TK, et al. Nephropathy in patients after Fontan palliation. Int J Cardiol 2009;132:244-7.
19. Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg 2005;129:1348-52.
20. Alphonso N, Baghai M, Sundar P, et al. Intermediate-term outcome following the Fontan operation: a survival, functional and risk-factor analysis. Eur J Cardiothorac Surg 2005;28:529-35.
21. Kirklin JW, Fernandez G, Fontan F, et al. Therapeutic use of right atrial pressures early after the Fontan operation. Eur J Cardiothorac Surg 1990;4:2-7.
22. Mitchell MB, Campbell DN, Ivy D, et al. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J Thorac Cardiovasc Surg 2004;128:693-702.
23. Presson RG, Baumgartner WA, Peterson AJ, et al. Pulmonary capillaries are recruited during pulsatile flow. J Appl Physiol 2002;92:1183-90.
24. Khambadkone S, Li J, de Leval MR, et al. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 2003;107:3204-8.
25. Busse R, Fleming I. Pulsatile stretch and shear stress: physical stimuli determining the production of endothelium-derived relaxing factors. J Vasc Res 1998;35:73-84.
26. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
27. Lévy M, Danel C, Laval AM, et al. Nitric oxide synthase expression by pulmonary arteries: a predictive marker of Fontan procedure outcome? Thorac Cardiovasc Surg 2003;125:1083-90.
28. Hiramatsu T, Imai Y, Takanashi Y, et al. Time course of endothelin-1 and adrenomedullin after the Fontan procedure. Ann Thorac Surg 1999;68:169-72.
29. Yamagishi M, Kurosawa H, Hashimoto K, et al. The role of plasma endothelin in the Fontan circulation. J Cardiovasc Surg (Torino) 2002;43:793-7. (Pubitemid 36040810)
30. Hiramatsu T, Imai Y, Kurosawa HM, et al. Effects of dilutional and modified ultrafiltration in plasma endothelin-1 and pulmonary vascular resistance after the Fontan procedure. Ann Thorac Surg 2002;73:861-5.
31. Inai K, Nakanishi T, Nakazawa M. Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation. Am Heart J 2005;150:588-94.
32. Mavroudis C, Deal BJ, Backer CL. The beneficial effects of total cavopulmonary conversion and arrhythmia surgery for the failed Fontan. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002;5:12-24.
33. Eberlein MH, Drummond MB, Haponik EF. Plastic bronchitis: a management challenge. Am J Med Sci 2008;335:163-9.
34. Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, et al. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol 2004;44:20-72.
35. Tjan TD, Scheld HH, Schmid C. Heart transplantation after Fontan's procedure with bilateral cavopulmonary connections. Thorac Cardiovasc Surg 2006;54:210-12.
36. Coskun TS, Coskun OK, El Arousy M, et al. Heart transplantation after Fontan procedure in adults. ASAIO J 2007;53:e3-4.
37. Mitchell MB, Campbell DN, Boucek MM. Heart transplantation for the failing Fontan circulation. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004;7:56-64.
38. Lamour JM, Kanter KR, Naftel DC, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease; cardiac transplant registry database; pediatric heart transplant study. J Am Coll Cardiol 2009;54:160-5.
39. Griffiths ER, Kaza AK, Wyler von Ballmoos MC, et al. Evaluating failing fontans for heart transplantation: predictors of death. Ann Thorac Surg 2009;88:558-63.
40. Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2010;139:85-91.
41. Ghanayem NS, Berger S, Tweddell JS. Medical management of the failing Fontan. Pediatr Cardiol 2007;28:465-71.
42. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107:996-1002.
43. Kouatli AA, Garcia JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997;96:1507-12.
44. Ohuchi H, Hasegawa S, Yasuda K, et al. Severely impaired cardiac autonomic nervous activity after the Fontan operation. Circulation 2001;104:1513-18. (Pubitemid 32917344)
45. Ishibashi N, Park IS, Takahashi Y, et al. Effectiveness of carvedilol for congestive heart failure that developed long after modified Fontan operation. Pediatr Cardiol 2006;27:473-5.
46. Donnelly JP, Rosenthal A, Castle VP, et al. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 1997;130:474-8.
47. Kelly AM, Feldt RH, Driscoll DJ, et al. Use of heparin in the treatment of proteinlosing enteropathy after Fontan operation for complex congenital heart disease. Mayo Clin Proc 1998;73:777-9.
48. Facchini M, Guldenschuh I, Turina J, et al. Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia. J Cardiovasc Surg (Torino) 2000;41:567-70.
49. Thacker D, Patel A, Dodds K, et al. Abstract 1794: Use of oral budesonide in the management of protein losing enteropathy after the Fontan operation. Circulation 2009;120:S556.
50. Ryerson L, Goldberg C, Rosenthal A, et al. Usefulness of heparin therapy in proteinlosing enteropathy associated with single ventricle palliation. Am J Cardiol 2008;101:248-51.
51. Ringel RE, Peddy SB. Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol 2003;91:1031-2.
52. Glöckler M, Severin T, Arnold R, et al. First description of three patients with multifocal lymphangiomatosis and protein-losing enteropathy following palliation of complex congenital heart disease with total cavo-pulmonary connection. Pediatr Cardiol 2008;29:771-4.
53. Haworth SG, Hislop AA. Pulmonary hypertension: treatment and survival in children with pulmonary arterial hypertension: the uk pulmonary hypertension service for children 2001e2006. Heart 2009;95:312-17.
54. Uzun O, Wong JK, Bhole V, et al. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006;82:e39-40.
55. Yoshimura N, Yamaguchi M, Oka S, et al. Inhaled nitric oxide therapy after Fontantype operations. Surg Today 2005;35:31-5.
56. Cai J, Su Z, Shi Z, et al. Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan-type procedure: a prospective, randomized study. Ann Thorac Surg 2008;86:882-8.
57. Cai J, Su Z, Shi Z, et al. Nitric oxide in conjunction with milrinone better stabilized pulmonary hemodynamics after Fontan procedure. Artif Organs 2008;32:864-9.
58. Takahashi K, Mori Y, Yamamura H, et al. Effect of beraprost sodium on pulmonary vascular resistance in candidates for a Fontan procedure: a preliminary study. Pediatr Int 2003;45:671-5.
59. Miyaji K, Nagata N, Miyamoto T, et al. Combined therapy with inhaled nitric oxide and intravenous epoprostenol (prostacyclin) for critical pulmonary perfusion after the Fontan procedure. J Thorac Cardiovasc Surg 2003;125:437-9.
60. Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008;29:1681-7.
61. Haseyama K, Satomi G, Yasukochi S, et al. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2006;132:1232-3.
62. Clinical trial NCT00507819. Sildenafil after the Fontan operation (Children's Hospital of Philadelphia). http://www.clinicaltrial.gov/ct2/show/ NCT00507819 2009 (accessed May 2010).
63. Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3:887-900.
64. Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertensionwith the focus on the mildly symptomatic patient. Vasc Health Risk Manag 2009;5:607-19.
65. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005;24:1174-6.
66. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25:502-8.
67. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44.
68. Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients with a failing Fontan circulation: a multicenter pilot study. Cardiol Young 2009;19:331-9.